Story excerpt provided by Cincinnati Business Courier.
Written by Barrett J. Brunsman.
Aerpio Pharmaceuticals Inc. revealed today it raised $40 million by issuing 8 million shares of common stock, which will be used to develop clinical programs such as a treatment for eye disease related to diabetes.
The stock, priced at $5 a share, was sold to “accredited investors.” The offering was exempt from registration under the Securities Act.
Click here to read the complete article.
Originally published March 16, 2017.